HYHae Yong Yoo

Hae Yong Yoo

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Hae Yong Yoo has a total of 41 co-authors. Here are the top co-authors by number of shared publications:

  • Young Hyeh Ko

    Samsung Medical Center, Department of Pathology Sungkyunkwan University School of Medicine Seoul Republic of Korea

    4 shared publications
  • Seung Ho Choi

    Department of Health Sciences and Technology, Samsung Advanced Institute for Health Sciences and Technology, Sungkyunkwan University, Seoul 06355, Korea; Samsung Biomedical Research Institute, Research Institute for Future Medicine, Samsung Medical Center, Seoul 06355, Korea

    3 shared publications
  • Eun Seon Kim

    Department of Health Sciences and Technology, Samsung Advanced Institute for Health Sciences and Technology, Sungkyunkwan University, Seoul, Korea

    2 shared publications
  • Kyoungjoo Cho

    Department of Life Science, College of Fusion Science, Kyonggi University, Suwon, Korea

    2 shared publications
  • Seok Jin Kim

    Department of Health Sciences and Technology, Samsung Advanced Institute of Health Sciences and Technology, Sungkyunkwan University, Seoul, Korea

    2 shared publications
  • Do Hyoung Lim

    1 shared publication

Latest Publications

  • Open Access

    Interaction of CSN4 to DDB1 regulates its stability and function in DNA damage signaling

    by Seung Ho Choi, Kyoungjoo Cho, Eun Seon Kim, Hae Yong Yoo

    The COP9 signalosome (CSN) regulates Cullin–RING E3 ligases (CRLs) through deneddylation and complex stabilization. However, the specific molecular functions of individual CSN subunits remain unclear. In this study, we identified CSN4 as a critical regulator of DDB1 stability and CRL4 function during the cellular response to DNA damage. CSN4 binds directly to DDB1, and its loss leads to the destabilization of DDB1, reduced CRL4 assembly, and impaired DNA damage-induced ubiquitination. The DDB1 K1131R mutant did not exhibit downregulated DDB1 expression, owing to CSN4 depletion. CSN4-resistant property showed different results in the DNA damage response, indicating that this protein is essential for the function of DDR-associated CRL. Our results also showed that This CSN4 deficiency induces autophagy, which is utilized for the degradation of DDB1. These findings provide new insights into the coordination between the ubiquitin–proteasome system and autophagy pathways in the DNA damage response. Keywords : DDB1, CSN4, Autophagy-mediated degradation, Ubiquitin-proteasome system, COP9 signalosome, CRL4 ubiquitin ligase

  • Open Access

    Regulation of cellular states via targeted phosphorylation of p53 using a nanobody-coupled kinase system

    by Hoe Eun Lim, Hae Yong Yoo

    Phosphorylation participates in numerous signal transduction processes, including proliferation, differentiation, apoptosis, and cellular response to stimuli. Understanding its regulatory mechanisms is essential for advancing therapeutic interventions. In this study, we developed a target protein phosphorylation (TPP) system, consisting of a nanobody fused to a kinase domain, to investigate its ability to phosphorylate target proteins and regulate their cellular characteristics. We first verified that the nanobody-coupled kinase effectively phosphorylates GFP. Subsequently, we focused on p53 phosphorylation, identifying specific phosphorylation sites targeted by the system. This phosphorylation resulted in stabilization of p53 protein levels, inducing p21 expression, delaying cell cycle progression and suppressing cell growth. Furthermore, combining the TPP system with chemotherapeutic drugs (5-Fluorouracil and Oxaliplatin) enhanced cytotoxicity in colorectal cancer cells. The TPP system achieved p53 phosphorylation without external stimuli, inducing a DNA-damaged state in cells. In vivo, doxycycline-induced expression of the TPP system in a xenograft mouse model significantly inhibited tumor growth. This work demonstrates the ability to phosphorylate key regulatory proteins and alter cellular states, suggesting applications in studying phosphorylation-related pathways and developing therapies for diseases associated with dysregulated phosphorylation.


  • Open Access

    Interaction of DDB1 with NBS1 in a DNA Damage Checkpoint Pathway

    by Hoe Eun Lim, Hee Jung Lim, Hae Yong Yoo

    Various DNA damage checkpoint control mechanisms in eukaryotic cells help maintain genomic integrity. Among these, NBS1, a key component of the MRE11-RAD50-NBS1 (MRN) complex, is an essential protein involved in the DNA damage response (DDR). In this study, we discovered that DNA damage-binding protein 1 (DDB1) interacts with NBS1. DDB1 is a DDR sensor protein found in UV-induced DNA replication blocks. Through pull-down and immunoprecipitation assays conducted in Xenopus egg extracts and human cell lines, we demonstrated a specific interaction between NBS1 and DDB1. DDB1 was also found to associate with several proteins that interact with NBS1, including DNA topoisomerase 2-binding protein 1 (TopBP1) and Mediator of DNA damage checkpoint protein 1 (MDC1). Notably, the interaction between DDB1 and NBS1 is disrupted in MDC1-depleted egg extracts, indicating that MDC1 is necessary for this interaction. Furthermore, the depletion of DDB1 leads to increased Chk1 activation upon DNA damage. These novel findings regarding the interaction between NBS1 and DDB1 provide new insights into how DDB1 regulates DNA damage pathways.


  • Open Access

    The mutation of BCOR is highly recurrent and oncogenic in mature T-cell lymphoma

    by Jin Hyun Kang, Seung Ho Lee, Jawon Lee, Murim Choi, Junhun Cho, Seok Jin Kim, Won Seog Kim, Young Hyeh Ko, Hae Yong Yoo

    Background: BCOR acts as a corepressor of BCL6, a potent oncogenic protein in cancers of the lymphoid lineage. We have found the recurrent somatic mutation of BCOR occurred in mature T-cell lymphoma (TCL). The role of BCOR mutation in lymphoid malignancies is unknown.Methods: Lymphoma patient samples were analyzed to identify missense mutations in BCOR using Sanger sequencing. Transfection, RNA interference, immunoprecipitation, western blotting, cell proliferation, cytokine assays and quantitative real-time PCR were employed to determine the functional relevance of the novel K607E mutation in BCOR. The significant transcriptional changes were analyzed by performing DNA microarray profiling in cells expressing BCOR K607E mutant.Results: One hundred thirty-seven lymphoma patient samples were analyzed to identify K607E mutation of the BCOR gene. The BCOR K607E mutation was identified in 15 of 47 NK/T cell lymphoma cases (31.9%), 2 of 18 angioimmunoblastic T-cell lymphoma cases (11.1%), 10 of 30 peripheral T-cell lymphoma, not otherwise specified cases (33.3%), and 13 of 42 diffuse large B-cell lymphoma cases (30.9%). Molecular analysis of BCOR K607E mutation revealed that compared to the wild-type BCOR, the mutant BCOR bound to the BCL6, PCGF1, and RING1B proteins with lesser affinity. Ectopic expression of BCOR K607E mutant significantly enhanced cell proliferation, AKT phosphorylation and the expression of interleukin-2 (IL-2) with up-regulated expression ofHOXand S100 protein genes in T cells. BCOR silencing also significantly enhanced cell proliferation, AKT phosphorylation, and IL-2 production.Conclusions: Functional analyses indicated that K607E mutation of BCOR is oncogenic in nature and can serve as a genetic marker of T-cell lymphoma.


  • Open Access

    A highly recurrent novel missense mutation in CD28 among angioimmunoblastic T-cell lymphoma patients

    by S. H. Lee, J. S. Kim, J. Kim, S. J. Kim, W. S. Kim, S. Lee, Y. H. Ko, H. Y. Yoo

    Angioimmunoblastic T-cell lymphoma (AITL) is a rare, aggressive type of T-cell lymphoma (TCL) that accounts for 18.5% of mature T-cell or natural killer (NK)-cell lymphomas.[1][1] Mutations in the IDH2, TET2 , and DNMT3A genes, frequently seen in various types of cancer, have also been linked to


    • 1 June 2015
      • Vol. 35  (6) , 3333-40

    Microarray Gene-expression Profiling Analysis Comparing PCNSL and Non-CNS Diffuse Large B-Cell Lymphoma.

    by Do Hyoung Lim, Won Seog Kim, Seok Jin Kim, Hae Yong Yoo, Young Hyeh Ko

    The purpose of the present study was to compare microarray gene-expression profiling data between primary central nervous system (CNS) lymphoma and non-CNS lymphomas. We performed whole-genomic cDNA-mediated annealing, selection and ligation assay with 177 formalin-fixed paraffin-embedded tumor samples. We identified 20 differentially expressed genes out of which 5 were predominantly expressed in CNS DLBCL compared to non-CNS DLBCL (C16orf59, SLC16A9, HPDL, SPP1, and MAG). SLC16A9 may be involved in aerobic glycolysis of malignant tumors. The alteration in gene expression of SPP1 in primary CNS lymphoma is involved in biological activity, such as CNS tropism, B-cell migration, proliferation, and aggressive clinical behavior. MAG may be an important adhesion molecule that contributes to perineural cancer invasion. Genomic differences between CNS and non-CNS DLBCL exist and the most prominent genes are SPP1 and MAG. SPP1 may play a key role in CNS tropism of primary CNS lymphoma.


  • Open Access

    Identification of Sestrin3 Involved in the In vitro Resistance of Colorectal Cancer Cells to Irinotecan

    by Seung Ho Choi, Hye Kyung Hong, Yong Beom Cho, Woo Yong Lee, Hae Yong Yoo

    Irinotecan, an analogue of camptothecin, is frequently used as a single agent or in combination with other anticancer drugs for the treatment of colorectal cancer. However, the drug resistance of tumors is a major obstacle to successful cancer treatment. In this study, we established that cells acquire chronic resistance to irinotecan. We profiled their differential gene expression using microarray. After gene ontology (GO) and KEGG pathway analysis of the microarray data, we specifically investigated whether Sestrin3 could decrease irinotecan resistance. Our results revealed that Sestrin3 enhanced the anticancer effect of irinotecan in vitro in LoVo cells that had acquired resistance to irinotecan. Irinotecan-resistant LoVo cells showed lower reactive oxygen species (ROS) production than their irinotecan-sensitive parental cells. ROS production was increased by Sestrin3 knockdown in irinotecan-resistant LoVo cells. Our results indicate that Sestrin3 might be a good target to develop therapeutics that can help to overcome resistance to irinotecan.


  • Integrated copy number and gene expression profiling analysis of epstein–barr virus‐positive diffuse large b‐cell lymphoma

    by Heejei Yoon, Sanghui Park, Hyunjeong Ju, Sang Yun Ha, InSuk Sohn, Jisuk Jo, In‐Gu Do, Sookee Min, Seok Jin Kim, Won Seog Kim, et al.

    Viral oncogenes and host immunosenescence have been suggested as causes of Epstein‐Barr virus‐positive diffuse large B‐cell lymphoma (EBV + DLBCL) of the elderly. To investigate the molecular genetic basis of immune evasion and tumor outgrowth, we analyzed copy number alterations (CNAs) and gene expression profiles in EBV + DLBCL samples compared with EBV − DLBCL. There were relatively few genomic alterations in EBV + DLBCL compared with those detected in EBV‐negative DLBCL. The most frequent CNAs (>30%) in EBV + DLBCLs were gains at 1q23.2–23.3, 1q23.3, 1q32.1, 5p15.3, 8q22.3, 8q24.1–24.2, and 9p24.1; losses at 6q27, 7q11.2, and 7q36.2–36.3 were also recurrent. A gene expression profile analysis identified the host immune response as a key molecular signature in EBV + DLBCL. Antiviral response genes, proinflammatory cytokines, and chemokines associated with the innate immune response were overexpressed, indicating the presence of a virusinduced inflammatory microenvironment. Genes associated with the B‐cell receptor signaling pathway were downregulated. An integrated analysis indicated that SLAMF1 and PDL2 were key targets of the gains detected at 1q23.2–23.3 and 9p24.1. The chromosomal gain at 9p24.1 was associated with poor overall survival. Taken together, our results led to the identification of recurrent copy number alterations and distinct gene expression associated with the host immune response in EBV + DLBCL. We suggest that the upregulation of PDL2 on 9p24.1 promotes immune evasion and is associated with poor prognosis in EBV + DLBCL.